Ensign Peak Advisors, Inc Atreca, Inc. Transaction History

Ensign Peak Advisors, Inc

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 13, 2023	SELL	$0.78 - $1.68 $31,108 - $67,003	-39,883 Reduced 27.47%	105,283 $84,000
Q1 2022 May 16, 2022	BUY	$1.61 - $5.2 $233,717 - $754,863	145,166 New	145,166 $460,000
Q4 2021 Feb 11, 2022	SELL	$2.87 - $6.29 $1.8 Million - $3.95 Million	-628,536 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$7.82 - $13.8 $75,509 - $133,252	9,656 Added 1.56%	628,536 $5.36 Million
Q1 2021 May 12, 2021	BUY	$13.0 - $19.34 $6.49 Million - $9.65 Million	498,964 Added 416.09%	618,880 $9.49 Million
Q4 2020 Feb 12, 2021	BUY	$13.03 - $17.09 $565,072 - $741,142	43,367 Added 56.65%	119,916 $1.94 Million
Q3 2020 Nov 12, 2020	BUY	$12.67 - $23.19 $812,755 - $1.49 Million	64,148 Added 517.28%	76,549 $1.07 Million
Q2 2020 Aug 12, 2020	BUY	$12.52 - $23.45 $155,260 - $290,803	12,401 New	12,401 $264,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

Stay updated on Ensign Peak Advisors, Inc with notifications on news.